LENZ LENZ Therapeutics
- 22.360
- -0.840-3.62%
- 22.360
- 0.0000.00%
LENZ Therapeutics News
LENZ Therapeutics Analyst Ratings
H.C. Wainwright Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $38
Leerink Partners Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Announces Target Price $36
Leerink Partners Maintains LENZ Therapeutics(LENZ.US) With Buy Rating
Raymond James Initiates LENZ Therapeutics(LENZ.US) With Buy Rating, Announces Target Price $37
Piper Sandler Maintains Overweight on LENZ Therapeutics, Maintains $36 Price Target
BofA Securities Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $31
Piper Sandler Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $36
LENZ Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target
H.C. Wainwright Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $38
BofA Securities Initiates LENZ Therapeutics(LENZ.US) With Buy Rating, Announces Target Price $31
LENZ Therapeutics Price Target Announced at $38.00/Share by HC Wainwright & Co.
LENZ Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Intuitive Surgical (ISRG) and Silence Therapeutics (SLN)
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target
Sarepta Therapeutics Inc: Royal Bank of Canada cuts industry performance from outperforming the market; cuts target price from $157 to $142
Analysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), Tango Therapeutics (TNGX)
Tango Therapeutics, Inc.: H.C. Wainwright cuts target price from $16 to $13
CytomX Therapeutics Analyst Ratings
No Data